Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) announced today that Klee Irwin, CEO, has been invited to be a speaker at the 2022 Medical Psychedelics Series at Davos.

Every year, about 10,000 of the world’s foremost thinkers, leaders, decision-makers, investors, artists, and innovators descend upon Davos, Switzerland. This year, psychedelics and how they relate to the global mental health crisis will be part of the Davos events. The Medical Psychedelic Series brings together thought leaders, policy specialists, scientists, entrepreneurs, and other key industry participants and influencers. Discussions will include the disruptive impact of psychedelic-assisted mental healthcare.

Mr. Irwin’s presentation will be on May 25, 2022, at 1:30 pm Central European Time (CET, or 7:30 am EST), and is titled: Armageddon, PTSD, and Psychedelics, The Responsibility of World Brands in the Mental Health Crisis.

Mr. Irwin will also participate in a panel discussion, titled: Patient Access to Psychedelic Medicine

The discussion will run on Wednesday, May 25, 2022, at 12:00 pm CET (6:00 am EST)

Those not attending in person are able to register for the Livestream via psyched.co

From pandemics to wars around the world, subclinical PTSD and anxiety-induced mental health disorders have reached an alarming level. Mental health often tracks to trauma and violent trauma maps roughly to people’s income. Accordingly, those in our global society who need psychedelic mental health treatment the most are the least able to afford it. This talk is about how trusted household name brands must step into the emergency with a philanthropic motivation to use their brand power and economies of scale to drive down patient costs.

As founder of Irwin Naturals, one of the world’s leading nutraceutical brands with a 28-year track record of consistent profitability, the Company is now branching out into psychedelics assisted treatments through the roll-up of ketamine clinics towards establishing the world’s largest chain of clinics offering this ground-breaking and amazingly efficacious treatment.

Klee Irwin, CEO, commented, “It is an absolute honor to be invited to speak at the Davos ’22 Medical Psychedelics Series. Ensuring this incredibly effective treatment is available to all those who need it and not just those with a high disposable income, is a core mission of the Company and me personally. This event presents a unique opportunity to align the industry, scientists, influencers, and decision-makers towards making this happen. I look forward to connecting with other industry participants and build connections that will help further our mission.”

About Klee Irwin

28-years ago, Klee Irwin founded Irwin Naturals with a simple mission – to heal the world with plant medicine. He had no equity or bank financing. So, he formulated products to have curiously potent effectiveness relative to competitors – since word-of-mouth was his only hope against larger companies that put more money into advertising than ingredient cost. A cult brand emerged over the years, and his company now leads in most categories in which it competes. He has taken a philanthropic approach and has, for ethical reasons, chosen to sell CBD at less than half the price of virtually all competitors.

Klee is also the founder of Quantum Gravity Research, a non-profit research institute that he founded in 2009. The mission of the organization is to discover the geometric first-principles unification of space, time, matter, energy, information, and consciousness. As the Director of QGR, Klee manages a dedicated team of mathematicians and physicists in developing emergence theory to replace the current disparate and conflicting physics theories. Since 2009, the team has published numerous papers and journal articles analyzing the fundamentals of physics.

Outside of his work in physics, Klee is active in supporting students, scientists, educators, and founders in their aim toward discovering solutions to activate positive change in the world. He has supported and invested in a wide range of people, causes and companies including Change.org, Upworthy, Donors Choose, Moon Express, Hana Arts on Maui, Hero Science Foundation, Mayasil, the X PRIZE Foundation, and Singularity University where he is an Associate Founder.

A highly engaging speaker, Klee is one of the recognized thought leaders in the sector. He is working tirelessly to make Ketamine available to all those who need it, not just to those who can afford it, a topic covered in greater detail during his presentation.

About Irwin Naturals

Irwin Naturals has been a household name and best-in-class nutraceutical company since 1994. It is now leveraging its brand into both the cannabis and psychedelic sectors. On a mission to heal the world with plant medicine, Irwin has operated profitably for over 27 years*. The growing portfolio of products is available in more than 100,000 retail doors across North America, where 80% of households know the Irwin Naturals brand**. In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products into the mass market. The Company is now leveraging its famous halo of brand trust to become, perhaps, the first household name brand to offer THC-based products. Its rapidly growing national chain of psychedelic mental health clinics is called Irwin Naturals Emergence.

*Under several corporate structures, Klee Irwin has operated the Irwin brand profitably since 1994, as measured by EBITDA adjusted for extraordinary costs.

**Based on a formal Company survey with a sample size of 500 randomly selected adults.

For investor-related information about the Company, please visit ir.irwinnaturals.com/

To contact the Company’s Investor Relations department, please call toll-free at (800) 883-4851 or send an email to Investors@IrwinNaturals.com.

“Klee Irwin”

________________________________

Klee Irwin

Chief Executive Officer

T: 310-306-3636
investors@irwinnaturals.com

Regulatory Overview

The following is a brief summary of regulatory matters concerning ketamine in the United States (“US”). Under the Controlled Substances Act (21 U.S.C. § 811) (the “CSA”), ketamine is currently a Schedule III drug as well as being listed under the associated Narcotic Control Regulations, and psilocybin is currently a Schedule I drug.

Most US States have enacted Controlled Substances Acts (“State CSAs”) which regulate the possession, use, sale, distribution, and manufacture of specified drugs or categories of drugs and establish penalties for State CSA violations and form the basis for much state and local drug laws enforcement activity. State CSAs have either adopted drug schedules identical or similar to the federal CSA schedules or, in some instances, have incorporated the federal scheduling mechanism. Among other requirements, some US States have established a prescription drug monitoring or review programs collect information about prescription and dispensing of controlled substances for the purposes of monitoring, analysis and education.

In the United States, facilities holding or administering controlled substances must be registered with the US Drug Enforcement Agency (“DEA”) to perform this activity. As such, medical professionals and/or the clinics in which they operate, as applicable, are also required to have a DEA license to obtain and administer ketamine (a “DEA License”). While ketamine is a controlled substance in the United States, it is approved for general anesthetic induction under the US Food, Drug, and Cosmetic Act. Once a drug is approved for use, physicians may prescribe that drug for uses that are not described in the product’s labelling or that differ from those tested by the manufacturer and approved by the Food and Drug Administration (the “FDA”). Licensed medical practitioners may prescribe ketamine legally in Canada or the United States where they believe it will be an effective treatment in their professional judgment.

Please see Irwin’s filing statement on its SEDAR profile for more information on the regulatory environment and regulations surrounding the US THC industry.

Forward-Looking Information

This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Irwin Naturals Inc.

Arcview Capital today announced the launch of their equity crowdfunding platform, devoted to supporting cannabis and other adaptogenic plant-based businesses by democratizing investment in these rapidly scaling industries so that all who wish to participate can do so. With the addition of this full-service crowdfunding platform, Arcview Capital continues to expand upon its strategic partnership with trusted industry leader, The Arcview Group, to make investing in cannabis and other plant medicines uniquely simple. Perfectly timed to support growing markets, Arcview Capital’s crowdfunding platform will fuel growth in cannabis, psilocybin, and other plant-based modalities. Cannabis alone is predicted to generate some $25 billion in revenue in the U.S. by 2025.

“We’re excited to continue to be a thought leader on investing and capital raising in this industry. Our goal is always to provide new services that best support the business of cannabis,” says The Arcview Group’s CEO Jeffrey Finkle. “Today, Arcview Capital expands the power of our ecosystem with this new financial vehicle, benefiting companies seeking private investments in an environment where risk needs navigation but the opportunity is nearly limitless.”

“This is a full-service crowdfunding platform that is focused primarily on the cannabis industry. We are, to our knowledge, the first broker-dealer to offer such a focused crowdfunding platform in cannabis,” adds Arcview Capital CEO Philip Rothman. “Since its official introduction as a financial vehicle in 2015, crowdfunding has become a major force in raising funds, surpassing $2.5 billion in equity raised in the United States. It’s ideal for the cannabis space as crowdfunding enables both small and large investors to buy an interest in a company and support that company as it grows. With this launch, we further expand the capabilities of the Arcview ecosystem to support our clients where they need it most.”

Arcview Capital anticipates its first crowdfunding offerings to be live by the end of Q2 and is currently accepting applications. Click here for more information.

About Arcview Capital
Launched in 2020 with the ability to swiftly adapt to the rapidly changing market conditions and emerging trends, Arcview Capital is the first independent broker-dealer focused primarily on the ever-evolving cannabis industry. The firm helps companies raise capital to start or grow their business and customize the distribution channel based on their individual needs. Simultaneously, Arcview Capital provides opportunities for institutions and individuals to invest in private companies and funds.

Arcview Capital is an integral part of The Arcview Group ecosystem. The Arcview Group is an ecosystem of financial and consulting services and has been a trusted global leader for over 12 years, servicing the cannabis, hemp, and psychedelic industries. For more information, please visit www.arcviewcapital.com.

This release was prepared by Arcview Capital LLC, a member of FINRA and SIPC. It is for your information only and is not an offer or solicitation for the purchase or sale of any security or a recommendation or endorsement of any security or issuer. * Private placements are speculative investments in which an investor could potentially lose the entire investment. The risks associated with a private placement are stated in its private placement memorandum (“PPM”). Investors considering investing in a private placement should fully review the PPM, and if appropriate, consult a legal or financial professional prior to making an investment decision. * Cannabis Disclosure – Investments in the cannabis and cannabis-related industries carry numerous risks that you must be aware of before deciding to invest. We encourage you to speak with your own advisors prior to investing any money in any of the opportunities available through Arcview Capital. You can review our disclosures regarding the risks of investing in cannabis at: https://arcviewcapital.com/cannabis-legal-disclosure/. For additional information regarding the risks of investing with Arcview Capital, please visit our website: https://arcviewcapital.com.

MEDIA CONTACT:

Carolyn Matthies
The Arcview Group
+1 949-547-0645
carolynmatthies@arcviewgroup.com
Visit us on social media:
Facebook
Twitter
LinkedIn
Other

As world leaders come together to discuss the global economy at the World Economic Forum’s annual gathering, the world’s most prominent psychedelic industry leaders, drug development experts, clinicians, nonprofit organizations, advocates, and influencers will gather separately in Davos at the inaugural Medical Psychedelic Series to help shape the future of mental health.

“This is a one-of-a-kind opportunity for the medical psychedelics ecosystem to stand on the international stage for the first time in front of the world’s most powerful leaders,” says Marik Hazan, CEO of Energia Holdings Incorporated. “We want to spark conversations about the high unmet need in mental health, the future of FDA approved psychedelic-assisted therapy, provide a platform for establishing meaningful relationships and partnerships, and build trust with the global community,” added Maria Velkova, managing partner of Tabula Rasa Ventures.

The inaugural week-long series will take place from May 21-26, 2022, at the eclectic Medical Psychedelics House of Davos located on the Promenade in Davos, Switzerland.

Hosted by Energia Holdings Incorporated, the series includes educational talks and panels featuring some of the best-known figures in the psychedelic space, including acclaimed author and psychedelic medicine advocate Deepak Chopra; TV personality and advocate Jason Silva; countess of Wemyss and March, and nonprofit leader Amanda Fielding; psychedelic researcher David Nichols, Ph.D.; Endowed Professor & Vice Chair of Psychiatry, Icahn School of Medicine at Mount Sinai Rachel Yehuda, Ph.D. and many more.

The majority of conversations at the Medical Psychedelics House of Davos will focus on FDA approval for these compounds and their associated therapeutic potential, policy, safety and efficacy, biocultural preservation, drug development pipelines, and patient access.

Why Psychedelics: As the COVID-19 pandemic laid bare, mental health is one of the largest underserved areas in the medical community. With few solutions in sight, there is a growing body of evidence that suggests that psychedelic-assisted therapy could provide a breakthrough in treating countless mental health ailments, such as depression, substance abuse disorders, and PTSD.

What the Psychedelic Research Shows

“Clinical research findings published in recent years suggest that psychoactive compounds could be very effective for treating mental health ailments, though we still have a lot more research to conduct if we are to roll out these therapies in the safest possible way”, says Velkova.

The clinical evidence is accumulating. A recent publication in the prominent peer-reviewed journal Nature shows that 67% of patients no longer qualified for a PTSD diagnosis a year after treatment with MDMA (or “ecstasy”). Promising results have also been published for the treatment of depression and smoking cessation with psilocybin (psychoactive compound in “magic mushrooms”).

“We know that when the general public hears ‘psychedelics’ they first think about ‘shamans’ and ‘hippies’, but what we hope to show over our weeklong series is the evidence-based legitimacy behind psychedelics when used for treatment in clinical trials”, says Hazan.

At Davos 2022, This Medical Psychedelics Series Will Be the Global Platform for Where Select Attendees Will:

• Learn from leading experts in the medical psychedelics industry who are setting the narrative for both mental health and psychedelic therapeutics on the global stage in front of world leaders.

• Experience sessions curated to engage all six senses and give an unforgettable heart-opening, mind-stimulating, experience of human connection through sound meditation, breathwork, and conscious leadership workshops.

• Connect with psychedelic entrepreneurs, researchers, policymakers, and nonprofit leaders and some of the world’s most innovative psychedelic organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS), Maya Health, Compass Pathways, Imperial College London, and many others.

We invite you to join us on our mission to shape the principles, policies, and partnerships needed to support the medical psychedelics movement and transform the mental health crisis.

For any questions, please email us at: team@tabularasa.ventures

Can’t Make It in Person? We offer the ability to live stream and be a part of the immersive experience no matter where you are in the world. Join us virtually by signing up here.

Event Links:

Host Website:  Energia.co

Virtual Attendees: psyched.co

Media Partnerships: | press@energia.co

For Energia Holdings Inc. Media Inquiries:

POINT OF CONTACT: Marik Hazan

PHONE: +1.315.791.0211

E-MAIL: press@energia.co

About Energia Holdings Incorporated

Energia Holdings Incorporated (EHI) invests in, acquires, and operates companies that radically redefine the future of health by focusing on the blind spots of the current healthcare industry. We turn illcare into healthcare.

Energia Holdings Inc. 

Website: https://www.energia.co/

LinkedIn: https://www.linkedin.com/company/tabulaventures

Instagram: https://www.instagram.com/psychedstudio/

About Davos 2022

Every year, 10,000 of the world’s foremost thinkers, leaders, decision-makers, investors, artists, and innovators descend upon Davos, Switzerland – a tiny town in the alps that – for just a few days each year, transforms into the one place in the world where truly, anything is possible. Over the course of panels, meetings, and networking events, the global elite make the kinds of connections that shape the world today and have the potential to fundamentally impact its future. This will be the first year that medical psychedelics receive their own programming and six-day event series. Notable past Davos attendees include Jeff Bezos, George Soros, David Cameron, Bono, Leonardo DiCaprio, Sergey Brin, and many others.

Our Sponsors:

Maya Health

Indigenous Medicine Conservation Fund (IMCF)

Tabula Rasa Ventures

Irwin Naturals

Dr. Bronners

Field Trip Health

Microdose Psychedelic Insights

Journey Colab

Fireside Project

Four Sigmatic

Wavepaths

Riverstyx Foundation

Behold Retreats

Media Partners:

Psyched

ALTRD.TV

Microdose Psychedelic Insights

Disclaimers:

For Media Stakeholders: The city of Davos and the events that take place there are highly monitored and regulated. As such, we must be careful about the ways in which we speak about our events in a public forum. Any long-form publications, PR releases, or articles, must be approved by the Energia Holdings Inc. team before posting. Please send a copy to maya@energia.co for approval and please allow 48 hours for turnaround time.

Phat Lip, the all-new lip healing and moisturizing expert on the scene, has released its CBD & Terpene infused lip care line to finally show the world what luxurious lip care feels like. Phat Lip (developed by Ala Rassi) will be showcasing for the first time their all-new CBD & Terpene infused Lip Balm line as a sponsor of Cannabis Radio’s annual 420 Bud Bash Concert Series.

“We are excited to share this innovative new product with our customers at an accessible price point,” says Phat Lip CEO Amy Lovelace. “We have been working on perfecting this skin formula for years and am just beyond elated to finally share it with the world. Everyone deserves self-confidence and to be proud of their image knowing they have soft healthy lips — this lip balm formula gives our customers exactly that.”

In research, this combination of CBD & natural terpenes has been shown to have incredible properties such as:

• Anti Bacterial

• antibacterial compounds interfere with the growth and reproduction of bacteria on the topical level.

• Anti Inflammatory

• CDB infusion reduces swelling, pain, and redness from existing irritation

• Deeply Moisturizing

• Calming support is richly moisturizing, and also helps to maintain the skin’s natural balance.

• Mind Calming

• The ritual of applying CBD + Terpenes together on lips creates a multi-sensorial experience that soothes both the lips and the mind.

Phat Lip CBD & Terpene infused Lip Balm has a silky texture that absorbs into the skin quickly and acts immediately. The lip balm is packaged in easy-to-use long-lasting containers that reduce the risk of cross-contamination. Each Phat Lip also comes with its own elegant bag for easy carrying and storing at home or on the go.

Phat Lip brings together the brilliant formulation of Ala Rassi skincare and the award-winning design of Awaken Koala, a creative agency based in Miami, FL. “There is no better feeling as an entrepreneur than to see your product come to life and begin to serve the community that it was intended for,” said Phat Lip CEO Amy Lovelace. “We are proud to showcase the new lip balm formula we have been working so hard on this past year, and just beyond grateful to Bud Bash and Awaken Koala for their support .”

Phat Lip will announce winners of an exclusive 420 raffle on their Instagram page where followers to @feelphatlip will be eligible to win a free Trio Box featuring all 3 of the Phat Lip flavors, plus exclusive discounts will be available for attendees who come to visit their on-site display.

Read more about the Phat Lip packaging and ingredients.

The Phat Lip team has a strong passion to encourage self-confidence and self-expression which can be seen through their choice use of the hashtag #MindYourLips as seen on the @feelphatlip Instagram page. “We set out to design a product experience that is equally good for your mind and body,” says Phat Lip Creative Director Michael Gundich. “It’s our hope that the confidence our customers gain from interacting with the Phat Lip brand overflows to positively impact the rest of their life, one terpene infused kiss at a time”.

Mellow Fellow is the creation of the team at Florida-based Arvida Labs. “We are truly at the intersection of science and passion. While holding new patents on the newest cannabinoids along with our constant and comprehensive research and discovery,” said Mellow Fellow CEO Gerald S. Coombs Jr Ph.D. “We are proud to showcase our expansive product line of Delta 8, Delta 10, THC-O, and HHC blends at this wonderful holiday celebration at the Bud Bash.”

Mellow Fellow will announce winners of an exclusive 420 raffle on their Instagram page where followers to @mellowfellowfam will be eligible to win $1500 in free products, plus swag and deep discount products will be available for attendees to win and buy at their on-site display.

Mellow Fellow will include their “Exclusive 420 Bundle” for attendees of Bud Bash as well as on the Mellow Fellow website at a 75% discount.
The Exclusive 420 Bundle for 420 will include

• A Delta 8 disposable vape.
• Delta 9 edibles
• And a vape cartridge in your choice of cannabinoid (Delta 10/ THC-O or HHC)

The expert team at Mellow Fellow is proud to be the #1 brand you think of when looking for optimal levels of cannabis-derived wellness. All products are Pharmacist formulated, Ph.D. Chemist derived. All products are made in-house from start to end.

Cannabis Radio, the premier radio/ podcast network dedicated to all things Cannabis, hosted their last Bud Bash event in South Florida as a VIP black-tie affair aboard the luxurious SeaFair Luxury Yacht in Downtown Miami as part of the annual United States Cannabis Conference (and soon to include Psychedelic) Expo. The Expo is scheduled to return with a date soon to be announced.

“We have hosted the 2022 Bud Bash to rave reviews across the country and we are excited to bring this concert incarnation of the Bud Bash to our hometown making us the official 420 event for South Florida. That’s what the community needs today, a place to come together and celebrate,” said Cannabis Radio CEO Daron Babin.

About Cannabis Radio
Cannabis Radio is the premier online radio/podcast network community delivering radio programming about legal cannabis and other related markets. CannabisRadio.com educates, entertains, and provides access to the world’s leading experts and develops the voices of those with passion, integrity, and the ability to contribute to the cannabis and psychedelics economies. Please visit www.cannabisradio.com.com for more information.

About Arvida Labs

Arvida Labs is a leading manufacturer of rare cannabinoids. We are able to create phytocannabinoids via chemistry vs chromatography at scale. Using our patent-pending processes we have shown the ability to modify the chemical structure of CBD & CBG into the following rare cannabinoids: D8, D9, D10, THCv, THC-O-Acetate, Hexahydroxycannabinol, CBND, CBC, CBN. Mellow Fellow’s mission is to provide safe, pure, and effective products.

The BudBash is a celebration of a post-covid return to normalcy and precedes the US Cannabis and Psychedelics Expo returning this fall. Event producer, Daron Babin explains, “We have hosted our BudBash events around the country to rave reviews. We are so excited to bring it to our home state. Now more than ever people need to be connected. We have created an environment that is welcoming to all and there is something to inspire and enlighten everyone.

This is a 420 celebration worthy of the King of Modern Day Cannabis patients and enthusiasts alike. The event will feature

• An all-day concert, starting at 4 pm, with some of the top local and national bands
• Dispensaries onsite providing unbelievable 420 specials redeemable in-store
• A cornucopia of amazing vendors with deep discounts, food & alcohol.
• Giveaways, door prizes, and a safe place to have a great time throughout the evening.

Events kick off at 4 pm and run through the night with hourly door prizes and giveaways. Attendees are encouraged to arrive anytime up until midnight.

The musical lineup for the event includes Drifting Roots, The Shake, 59 Shop, TIdal Theory, Indigo I, and Dominic Delaney.

Due to the popularity of these events, early registration is recommended. The event is open to everyone over 18 years old. Early registrants also qualify for special giveaways and door prizes.

Current Sponsors Include

Mellow Fellow – Presenting Sponsor
Sunnyside Dispensary
PhatLip

Sponsorship Opportunities

Companies interested in participating as on-site vendors or sponsorship opportunities are invited to learn more about BudBash at the official website.

About CannabisRadio

Cannabis Radio is the premier online radio/podcast network community delivering radio programming about legal cannabis and other related markets. CannabisRadio.com educates, entertains, and provides access to the world’s leading experts and develops the voices of those with passion, integrity, and the ability to contribute to the cannabis and psychedelics economies.

Media Contact

CannabisRadio.com
Brandy Shapiro-Babin, 954-309-5578
brandy@cannabisradio.com